Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome
Not Applicable
- Conditions
- Sleep Apnea Syndrome
- Registration Number
- JPRN-UMIN000027645
- Lead Sponsor
- Fujita Health University respiratory medicine department
- Brief Summary
There is no significant difference in AHI (median: 48.3 times/hour on the first night, 50.2 times/hour on the second night p=0.58). Among the secondary endpoints, significant differences were found in sleep efficiency (median: 82.8% on first night, 87.8% on second night, p=0.004), REM sleep rate (median: 15.0% on first night, 21.2% on second night, p<0.001). There was no significant difference in the AHI of patients with severe sleep apnea before and after taking Suvorexant.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The patient 19 years or younger at the time of the agreement acquisition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change on the PSG data before and after the single using of orexin receptor antagonist Suvorexant 15 mg
- Secondary Outcome Measures
Name Time Method